Kate Hayden | TalkMarkets | Page 1

Kate Hayden

Private investor and journalist
Kate is a former chef turned financial writer and editor, with more than 15 years of market experience. After working as a healthcare analyst in the '00s, when IPOs became an endangered species, she moved into general editorial, but healthcare/biotech remains her primary area of interest.
Following: 28 Followers: 1840

All Contributions

Latest Posts
1 to 11 of 11 Posts
SaverOne: Publicly Traded Tech Startup With Highly Positively Skewed Risk-Reward Ratio
Tuesday, December 26, 2023 9:00 AM EDT
Bottom line, after a deep dive into the company we've determined that given SaverOne's valuation, the risk-reward opportunity is highly attractive.
In this article: SVRE
Read
Evogene - A Company With Valuable Assets Trading At Zero Enterprise Value
Thursday, June 22, 2023 9:17 AM EDT
From a sum-of-parts perspective, Evogene is likely worth many multiples of its market valuation today, even without ascribing any value to Evogene’s technology.
In this article: EVGN Also: ICL, ARKG, CTVA
Read
SOBRSafe: A Disruptive Stock Worth The Risk
Wednesday, December 21, 2022 10:36 AM EDT
If something is cheap enough, and interesting enough, and has some concrete indications of holding higher prices - and you are clear-eyed about it - 'risk' is not intrinsically bad.
In this article: IGV, SOBR
Read
One-On-One With BriaCell Therapeutics Corp. Management
Thursday, October 27, 2022 12:18 PM EDT
BriaCell's lead candidate is Bria-IMT, a whole-cell cancer immunotherapy, combined with Incyte’s retifanlimab, for advanced breast cancer. We asked BriaCell’s CEO, William Williams, about the rationale for the combination. 
In this article: WWWW, BCTX, BCTXW, INCY
Read
Making A Splash: Small Portfolio Company With Big Potential
Wednesday, September 21, 2022 8:30 AM EDT
After SBEV's latest earnings, EF Hutton set a target for the stock that is more than double its current price.
In this article: SBEV Also: BUD, KO, PEP
Read
Gain Therapeutics: Reasons For Optimism
Wednesday, August 10, 2022 9:00 AM EDT
In biotechnology, potential rules. And in Gain's case, the potential to not just treat but functionally cure at least some forms of Parkinson's Disease is strong enough to weather early-stage challenges.
In this article: GANX Also: SDGR, RLAY, EXAI
Read
Why Protalix Is Back On The Radar
Tuesday, April 19, 2022 8:55 AM EDT
After encountering bureaucratic hurdles, Protalix's PRX-102 has come through the BALANCE study with flying colors and is ready to reapply for its BLA.
In this article: PLX
Read
Stem Holdings: Getting In On Marijuana's Ground Floor
Monday, December 31, 2018 1:55 PM EDT
Stem Holdings is an American company listed both OTC and in Canada, well-established in Oregon and gaining a foothold in other states.
In this article: STMH Also: TLRY, CRON, CGC
Read
Kindred Healthcare Not A Good Bet For Individual Investor
Wednesday, August 16, 2017 11:58 AM EDT
Less than 5% of KND is held by individual investors, and the recent changes to its core mission underline why this is one best left to the professionals.
In this article: KND
Read
Why I'm Interested In PDL BioPharma
Wednesday, August 9, 2017 10:36 PM EDT
Satisfying my curiosity as to what happened to some venture-backed companies, in this case one called ESP Pharma. Its acquirer hit a rough patch but may be looking up.
In this article: PDLI Also: VRX, DEPO
Read
Naked Brands: An Interview With CEO Carole Hochman
Monday, April 10, 2017 8:42 AM EDT
Naked Brand Group has announced its intentions to merge with Bendon Ltd. The synergies are clear. We got a chance to interview Naked's CEO about the company's past, present and future.
In this article: NAKD
Read
1 to 11 of 11 Posts